Spotlight on agalsidase beta in fabry disease

BioDrugs

Volumn 21, Issue 4, 2007, Pages 269-271

  Keating, Gillian M ^a   Simpson, Dene ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID; PLACEBO;

DISEASE COURSE; DRUG TOLERABILITY; ENZYME DEFICIENCY; FABRY DISEASE; FEVER; HUMAN; LIPID STORAGE; LYSOSOME; PRIORITY JOURNAL; REVIEW; RIGOR; RISK REDUCTION; TARGET CELL; THERAPY EFFECT;

ALPHA-GALACTOSIDASE; FABRY DISEASE; HUMANS; INJECTIONS, INTRAVENOUS; ISOENZYMES; RECOMBINANT PROTEINS;

EID: 34547097519     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721040-00007     Document Type: Review

References (21)

1. Genzyme Corporation. Fabrazyme® (agalsidase beta) for intravenous infusion: prescribing information [online]. Available from URL: http://www.fabrazyme.com [Accessed 2005 Oct 5]
2. European Medicines Agency. Fabrazyme: summary of product characteristics [online]. Available from URL: http://www. emea.eu.int [Accessed 2007 Jan 3]
3. Lee K, Jin X, Zhang K, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003 Apr; 13 (4): 305-13
4. Eng CM, Banikazemi M, Gordon RE, et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001 Mar; 68 (3): 711-22
5. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001 Jul 5; 345 (1): 9-16
6. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007 Jan 16; 146 (2): 77-86
7. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 2007 May; 18 (5): 1547-57
8. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002 Dec; 62 (6): 1933-46
9. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004 Jul; 75 (1): 65-74
10. Thurberg BL, Byers HR, Granter SR, et al. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 2004 Apr; 122 (4): 900-8
11. Wraith J, on behalf of the AGAL-016 Study Investigators. Agalsidase beta (recombinant human α-galactosidase A) therapy in paediatric patients with Fabry disease [abstract]. 10th International Congress of Inborn Errors of Metabolism; 2006 Sep 12-16; Chiba
12. Eto Y, Ohashi T, Utsunomiya Y, et al. Enzyme replacement therapy in Japanese Fabry disease patients: the results of a phase 2 bridging study. J Inherit Metab Dis 2005; 28 (4): 575-83
13. Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol 2006; 97: 1515-8
14. Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003 Sep 16; 108 (11): 1299-301
15. Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's disease. Clin Genet 2004 Aug; 66 (2): 158-65
16. Breunig F, Beer M, Knoll A, et al. Kidney function, myocardial mass and late enhancement in 17 patients with Fabry disease after 1 year of enzyme replacement therapy [abstract no. MP142]. 41st Congress of the European Renal Association and the European Dialysis and Transplant Association; 2004 May 15-18; Lisbon
17. Guffon N. Stabilisation of kidney function in a group of 15 patients diagnosed with Fabry disease and treated with Fabrazyme® for a year [abstract no. W272]. World Congress on Nephrology; 2003 Jun 8-12; Berlin
18. Hilz MJ, Brys M, Marthol H, et al. Enzyme replacement therapy improves function of C-, Aδ-, and Aβ-nerve fibers in Fabry neuropathy. Neurology 2004 Apr 13; 62 (7): 1066-72
19. Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab 2005 Aug; 85 (4): 255-9
20. Guffon N, Fouilhoux A. Clinical benefit in Fabry patients given enzyme replacement therapy: a case series. J Inherit Metab Dis 2004; 27 (2): 221-7
21. Torregrosa V, de Arriba G, Checa D, et al. Health related quality of life in patients wtih Fabry disease treated with agalsidase beta: a twelve months follow-up study [abstract no. P34]. Fabry 5th Round Table Meeting; 2004 Oct 22-23; Warsaw